Podcasts about plgf

In this episode, you'll hear a conversation with three women's health experts about how early diagnostic testing is transforming care for heart disease, STIs, and preeclampsia. Discover how proactive screening empowers women, supports personalized care, and helps shift healthcare from reaction to prevention.   About Our Speakers:  Dr. Lindy Crimmins, Global Medical Affairs Manager. Lindy's clinical experience spans from emergency medicine to critical and primary care. Currently, she is responsible for providing medical support for the QuidelOrtho acute care menu throughout the product lifecycle. Lindy is passionate about education, testing guideline updates and assay utilization to drive improved patient-centered outcomes. Dr. Rea Castro, Director of Medical Affairs. Rea is a seasoned medical professional with extensive experience in pharmaceutical clinical development, biotechnology and diagnostic product development across multiple therapeutic areas, including immunology, oncology and women's health. She is currently a cross-functional leader in medical affairs and is committed to advancing healthcare outcomes through innovative research, quality healthcare delivery and rigorous safety standards. Vonda McAllister, Director of Global Product Management. Vonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.

This is the 11th episode in my Pharmacist Podcasters Series. My guests and I talk about podcasting to inspire you to start your own podcast, be a podcast guest, or use your voice in general. If you're interested in podcasting, pod-guesting or public speaking, you need to listen to this episode. My guest today is Dr. Danielle Plummer, host of the MaternalRx Podcast on the Pharmacy Podcast Network.    Pharmacists can play a crucial role in maternal health. Advocacy and education are critical in improving maternal care. Listen and learn from Dr. Plummer on the MaternalRx Podcast!    Click to read the FULL show notes: https://www.thepharmacistsvoice.com/podcast (select episode 329)   Bio - Danielle Plummer, PharmD (May 2025) Danielle Plummer, PharmD, is a third-generation pharmacist and host of the MaternalRx podcast on the Pharmacy Podcast Network. She earned her PharmD from Creighton University in 2016 and has since had a broad pharmacy career spanning retail, hospital, consulting, and medical affairs.   Combining clinical expertise with lived experience, Danielle specializes in supporting pregnant patients, particularly those suffering from Hyperemesis Gravidarum (HG). After studying treatments for other diseases of malnutrition in pharmacy school, she became certified in pharmacogenetics and as an antepartum doula. This, along with a community of pharmacy entrepreneurs, inspired her to launch HG Pharmacist©, a blog to share information about HG, which later grew into Obstet-Rx©, a consulting company offering personalized medication management and patient advocacy to women worldwide.   Her subject matter expertise has led to board member appointments, speaking engagements, and media contributions for international magazines. In her work as an MSL, she has supported diagnostics for preeclampsia (sFlt-1/PlGF) and procalcitonin, as well as therapies for iron deficiency anemia and small cell lung cancer.   Through her podcast, Danielle shows how pharmacists play a key role in improving maternal outcomes. (End bio)    Backstory Danielle and I met at Medipreneurs several years ago and have kept in touch. I enjoyed getting to know her better during this interview. She has transformed her career since we first met, and I'm proud of her for starting a podcast.    The Pharmacy Podcast Network is an important part of Danielle's story. They produce and distribute the MaternalRx Podcast on their network. If you'd like to start a podcast on the Pharmacy Podcast Network, please reach out to Todd Eury via email: publisher@pharmacypodcast.com.   Share this episode! If you know someone who might like the MaternalRx Podcast, please share this episode with them. If you would like to be a guest on the MaternalRx Podcast or nominate a guest for the MaternalRx Podcast, please contact Dr. Danielle Plummer through LinkedIn or her other social media channels. She is also open to pod-guesting on other podcasts and speaking at events. Reach out to Dr. Plummer directly through LinkedIn or her other social media channels.   Subscribe to or follow The Pharmacist's Voice ® Podcast on your favorite podcast player and YouTube to get each new episode right when it comes out.   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   Thank you for listening today. Happy Mother's Day if you're a Mom or a Mom-to-Be!   If you need help starting your podcast, I can help. Get my FREE eBook or audiobook version on kimnewlove.com/podcasting or Amazon https://amzn.to/4iAKNBs. I also teach a self-paced, online course and work with clients by-the-hour. Listen to my episodes about podcasting in my back catalog on thepharmacistsvoice.com/podcast.    Links from this episode  Danielle's Blog: https://pregnancyvomiting.com/  Danielle's consulting website: https://hgpharmacist.com/ Facebook Group: Extreme Pregnancy Vomiting Education https://www.facebook.com/groups/hgsolutions MaternalRx Podcast https://maternityrx.podbean.com/  Pharmacy Podcast Network https://pharmacypodcast.com/shows/  Todd Eury's email publisher@PharmacyPodcast.com  Danielle Plummer, PharmD on LinkedIn: https://www.linkedin.com/in/daniellerplummer Connect with Danielle on Instagram @obstet_rx https://www.instagram.com/obstet_rx/  Connect on Facebook https://www.facebook.com/HGClinicalSolutions  Subscribe to Danielle's YouTube Channel https://www.youtube.com/@hgpharmacist  Follow Danielle on Twitter (X) https://x.com/Obstet_Rx  Follow Danielle on Pinterest https://www.pinterest.com/hgpharmacist/    Resources Mentioned HER Foundation https://hyperemesis.org  Preeclampsia Foundation https://www.preeclampsia.org/  Pregnancy Sickness Support (UK) https://pregnancysicknesssupport.org.uk/  PharmGKB (Pharmacogenomics Knowledge Base) https://www.pharmgkb.org/  CPIC (Clinical Pharmacogenetics Implementation Consortium) https://cpicpgx.org/  ACOG (American College of Obstetricians and Gynecologists) https://www.acog.org/  UpToDate (Resource, Retail Pharmacists) https://www.wolterskluwer.com/en/solutions/uptodate/industries/retail-pharmacy  Lexicomp is now Lexidrug  Micromedex https://www.micromedexsolutions.com/home/dispatch  Medscape https://www.medscape.com/  A Dose of Support Podcast on Spotify (April 2021 with Vanessa Kasper DNP, Host) featuring guest Dr. Danielle Plummer, PharmD https://open.spotify.com/episode/5qSIGIQ7lw6yO9rKNwi8Jg?si=9e97101b886f4f26     Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX  ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Pronounce Drug Names Like a Pro © Online Course https://www.kimnewlove.com  ✅ FREE Podcasting eBook/audiobook combo https://www.kimnewlove.com/podcasting  ✅ Podcasting Online Course https://www.kimnewlove.com/podcasting  ✅ Private Podcasting Coaching or Consulting https://www.kimnewlove.com/private-coaching  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with the same coach who helped me get started (Dave Jackson from The School of Podcasting)! **Affiliate Link - NEW 9-8-23**      Thank you for listening to episode 329 of The Pharmacist's Voice ® Podcast.  If you know someone who would like this episode, please share it with them!   Pharmacist Podcasters Series Part 1 with Ola Latala, PharmD (The Pharmacist's Voice Podcast Episode 248) Part 2 with Deeb Eid, PharmD (The Pharmacist's Voice Podcast Episode 253) Part 3 with Justin Cole, PharmD (The Pharmacist's Voice Podcast Episode 257) Part 4 with Christina Fontana, PharmD The Pharmacist's Voice Podcast Episode 262 Part 5 with Tony Dao, PharmD The Pharmacist's Voice Podcast Episode 266 Part 6 with Dr. H (Hussam Hamoush, PharmD) The Pharmacist's Voice Podcast Episode 275 Part 7 with Julie Doan, PharmD The Pharmacist's Voice Podcast Episode 297 Part 8 with Tim Ulbrich, PharmD The Pharmacist's Voice Podcast Episode 306  Part 9 with Zain Syed, PharmD The Pharmacist's Voice Podcast Episode 310 Part 10 with Rachel Gainsbrugh, PharmD The Pharmacist's Voice Podcast Episode 323  Part 11 with Danielle Plummer, PharmD (TODAY!) 

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Third-Trimester NT-proBNP for Pre-eclampsia Risk Prediction: A Comparison With sFlt-1/PlGF in a Population-Based Cohort.

The Filtrate:Joel TopfSwapnil HiremathWith Special Guest:Michelle Hladunewich, Nephrologist at the University of TorontoMir Melamed, Maternal-Fetal Medicine at the University of TorontoEditor Simon TopfShow NotesPriscilla Smith's letter:Dear Joel and the Freely Filtered team,I am a long-time fan of your podcast and was looking forward to hearing your recently aired discussion of the Praecis study of sflt1:PlGF use in preeclampsia. Preeclampsia and renal disease in pregnancy are areas that many nephrologists report a lack of knowledge or confidence in discussing and managing. I am a nephrologist who has been co-leading a renal pregnancy clinic in London while writing a PhD on progression of renal disease in pregnancy. I have had the immense privilege of working with experts and key opinion leaders in preeclampsia research both in the UK and internationally. As you know, preeclampsia is a serious and significant condition contributing to global maternal mortality and is also associated with future CKD and CVD risk so is both relevant and important within our professional group.Sadly, I found myself disappointed by the episode and felt it was a missed opportunity. I appreciate that you had difficulties obtaining appropriate experts to join the discussion, but perhaps it would have been better to delay production. While you all valiantly proceeded to discuss this important study, the topic is complex and there appeared to be a lack of understanding of the surrounding literature and pathogenesis of preeclampsia. Sadly, the maternal medicine expert's comments at the end of the podcast added little as she seemed determine to negate any benefit from the results despite declaring she had no experience or expertise in the use of these biomarkers.There are many people who understand the clinical aspects of preeclampsia as well as having direct experience of the use and utility of these biomarkers who would have been able to contribute much to your conversation. I look forward to future discussions of renal disease in pregnancy on your podcast and would be happy to suggest some expert panellists if you ever find yourself stuck.Kind regards,Priscilla Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia (JCI 2003)sFlt background: Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta (PubMed)PlGF background: Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps (PubMed)The PRAECIS trial (NephJC | NEJM Evidence)

Atrial fibrillation (1:30), sFlt-1/PlGF ratio in preeclampsia (4:50), hyaluronic acid for wounds (6:40), substance misuse (9:00), nirsevimab (12:50), and AFP Clinical Answers (14:10).

Welcome to the second episode of season three of Conversations in Fetal Medicine, where we talk to Professor John Kingdom. Prof Kingdom's bio: John Kingdom is a consultant in Maternal-Fetal Medicine and Obstetrics at Mount SinaiHospital, University of Toronto, Canada, where he established their Placenta Clinic in 1999 with his career-long friend Rory Windrim. English by birth, John lived in the southern counties, then in the “Troubles” of Northern Ireland, before medical school Dublin, where he graduated from Trinity College in 1984. Living in the busy Rotunda Hospital in Dublin for 3 months, followed by a summer elective at the Fetal Medicine centre at the Queen Mother's Hospital Glasgow, the home of Obstetric Ultrasound, set him firmly on his career path. He spent the next decade as a trainee in Glasgow, before moving to UCH, London to one of the very few UK subspecialty training positions at that time in Fetal Medicine. He held a senior lecturer position at UCL for only 3 years, before making the decision to cross the Pond to take up a unique opportunity as a clinician-scientist in major MFM centre. There he managed a molecular pathology research lab linked with his work as a high-risk Obstetrician, producing over 400 basic and more clinical publications thus far in his career, including guidelines on placenta accreta spectrum disorder and fetal growth restriction. In 2017, John led the first launch of real-time placenta growth factor testing (PlGF) in North America, which in 2023 is fast changing many aspects of care in our specialty. Since 2013, John has been Chair of the Department of Obstetrics & Gynaecology, spanning a city of over 6 million. With over 300 consultants across all sub-specialities, working in a citywide network of 10 hospitals and over 40,000 births annually, UofT ObGyn now ranks second to Harvard. Mount Sinai MFM Division of over 20 consultants provides 24/7 in-house care in all dimension of Fetal Medicine, and is home to both the Ontario Fetal Centre and a new Complex Obstetrics Surgery program. Their city-wide MFM fellowship currently has 12 subspecialty trainees in 2-3 year programs, as a mix of Canadian and International trainees, including from the UK. John's current passion beyond his own research focuses on mentorship across the fellowship to consultant transition, and ongoing academic career development. In Fall 2023 he was elected to fellowship of the Canadian Academy of Health Sciences.Podcast information:We have not included any patient identifiable information, and this podcast is intended for professional education rather than patient information (although welcome anyone interested in the field to listen). Please get in touch with feedback or suggestions for future guests or topics: conversationsinfetalmed@gmail.com, or via Twitter (X) or Instagram via @fetalmedcast.Music by Crowander ('Acoustic romance') used under creative commons licence. Podcast created, hosted and edited by Dr Jane Currie.

Kari Alitalo discusses experiments that reveal how two related VEGF ligands trigger distinct biological outcomes by binding to the same receptor.

Sandro De Falco, Angiogenesis LAB, Institute of Genetics and Biophysics “A. Buzzati Traverso", CNR, Naples, ITALY speaks on "PlGF/VEGFR-1 axis in pathological angiogenesis: hypoxic modulation and specific inhibition". This seminar has been recorded by ICGEB Trieste

Hintergrund: Präeklampsie ist weltweit eine der Hauptursachen perinataler Morbidi- tät und Mortalität für Mutter und Kind. Die frühe und zuverlässige Identifikation von Patientinnen mit erhöhtem Erkrankungsrisiko ist demnach eines der erstrebenswerte- sten Ziele in der heutigen Geburtshilfe. Die Verfügbarkeit hochsensitiver und hoch- spezifischer physiologischer wie biochemischer Marker würde nicht nur die Erken- nung von Risikopatientinnen ermöglichen, sondern auch den Weg für eine frühe Dia- gnosestellung und rechtzeitige therapeutische Intervention ebnen sowie die Entwick- lung neuer therapeutischer Möglichkeiten vorantreiben. Ziele: Vorliegende Arbeit enthält die Analyse der Serummarker sFlt-1, PlGF und sEng und deren Vergleich mit dopplersonographisch erhobenen Daten. Signifikante Unterschiede zwischen dem gesunden Normalkollektiv und den Gruppen „Milde Prä- eklampsie“ und „Schwere Präeklampsie“ sollen gezeigt werden. Methoden: Im Zeitraum von 2006 bis 2008 wurden 108 Patientinnen ab 23 + 0 SSW bis zum Zeitpunkt der Entbindung in einer randomisierten prospektiven Studie unter- sucht, es ergaben sich daraus für die Gruppen Milde Präeklampsie, Schwere Prä- eklampsie und Normalkollektiv 11, 21 respektive 274 Datensätze. Dabei wurden je- weils die Serummarker sFlt-1, PlGF und sEng mittles ELISA Immunoassay quantifi- ziert und dopplersonographisch der Pulsatilitäts-Index der A. umbilicalis und Aa. ute- rinae erhoben sowie auf Persistenz eines persistierenden spätsystolischen Notch der Aa. uterinae geprüft. Ergebnisse: Vorliegende Arbeit ergab signifikante Unterschiede zwischen den Grup- pen Milde und Schwere Präeklampsie und dem Normalkollektiv bezüglich der Se- rumwerte sFlt-1, PlGF und sEng sowie der dopplersonographischen Daten. Schlussfolgerung: Die Kombination von Dopplersonographie und den Serummar- kern sFlt-1, PlGF und sEng stellt einen vielversprechenden Ansatz zur frühen Detek- tion von Präeklampsie dar, der zur Verbesserung von Diagnostik und therapeutischen Möglichkeiten in größer angelegten Studien unbedingt weiter verfolgt werden sollte.

Drs Fogelson and Browne give updates from the recent SMFM and AAGL conferences, and discuss new articles.  Topics include PLGF and IUGR, endometrial polyps, faking resumes, and more.  Thanks for listening!   Academic OB/GYN Podcast Episode 35 – Back From The Ashes

In this episode I discuss several articles from the January Issue of the Green an Grey journals, and a few articles from the Lancet to boot!  We discuss the prospective outcomes in thrombophilia, Metformin and Glyburide in GDM, Miso vs Pit for PPH, interstitial pregnancy,  and SFlt-1 and PLGF for detection of pre-eclampsia.  Thanks for […]

Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD. However, other growth factors, such as platelet-derived growth factor (PDGF) and placenta growth factor (PlGF), have a substantial impact on development of AMD. Previous reports indicate that sorafenib, an oral multikinase inhibitor, might have beneficial effects on exudative AMD. This study investigates the effects of sorafenib on light-induced overexpression of growth factors in human retinal pigment epithelial (RPE) cells. Methods Primary human RPE cells were exposed to white light and incubated with sorafenib. Viability, expression, and secretion of VEGF-A, PDGF-BB, and PlGF and their mRNA were determined by reverse transcription-polymerase chain reactions, immunohistochemistry and enzyme-linked immunosorbent assays. Results Light exposure decreased cell viability and increased expression and secretion of VEGF-A, PDGF-BB and PlGF. These light-induced effects were significantly reduced when cells were treated with sorafenib at a dose of 1 mu g/ml. Conclusion The results show that sorafenib has promising properties as a potential antiangiogenic treatment for AMD.

The role of members of the Vascular Endothelial Growth Factor (VEGF) family and their receptors in angiogenesis, progression and pathophysiology of pituitary tumours is still poorly understood. In the present work, the expression and localization of the angiogenic factor VEGF-A and the lymphangiogenic factor VEGF-C, as well as VEGF receptors (VEGFR-1, VEGFR-2, VEGFR-3 and neuropilin-1), have been studied in normal and tumoural pituitary tissue and in transformed pituitary tumour cell lines. In addition, the role and mechanism of action of VEGFR-1 ligands have been investigated in normal and transformed rat pituitary cells. Immunohistochemical investigations in 3 normal human adenohypophyses showed that VEGFR-2 and neuropilin-1 were localized in blood vessel endothelial cells, while VEGFR-1 was found in endocrine cells. VEGF-A significantly induced ACTH and prolactin secretion in normal rat pituitary cell cultures, indicating a role of VEGF-A and VEGFR-1 in the regulation of the secretion of these pituitary hormones. In contrast, VEGFR-2 and its co-receptor neuropilin-1 may be needed to maintain optimal intrapituitary vascularization and blood vessel permeability. Although no lymphatic vessels were identified in normal adenohypophysis, the lymphangiogenic factor VEGF-C and its receptor VEGFR-3 were detected by immunohistochemistry, suggesting the involvement of the VEGF-C/VEGFR-3 system, usually implicated in lymphangiogenesis, in the maintenance of blood vessel permeability. The expression of VEGFR-1, VEGFR-2 and neuropilin-1 in a series of 39 pituitary adenomas reflected the same immunohistochemical localization pattern as observed in the normal adenohypophysis tissue. It was highly heterogeneous and mostly no significant correlation with different parameters, such as: tumour type, tumour grade, proliferation index (PI) and blood vessel number, was noticed. Only the absence of VEGFR-2 and neuropilin-1 correlated with a low PI, suggesting a role of these two receptors in increasing vessel permeability and consequently the availability of nutrients and oxygen for tumour cells. Functional studies, with the VEGFR-1-positive somatotrophinoma rat pituitary cell line MtT-S, showed that VEGF-A and the VEGFR-1 specific ligand PlGF, significantly stimulated the cell proliferation, through the activation of PI3K pathway and the induction of the anti-apoptotic factor Bcl-2 and the cell cycle promoter cyclin D1. VEGF-C immunostaining was detected in endocrine tumour cells of 10 adenomas and VEGFR-3 immunopositive vessels were found in 22 tumours, even if only 9 of them were positive for both VEGFR-3 and LYVE-1 (specific lymphatic vessel marker), suggesting that the VEGF-C/VEGFR-3 system may have a role in the regulation of tumour angiogenesis of pituitary adenomas, rather than in lymphangiogenesis, as already shown in other tumour types. In conclusion, the results of the present study provide strong evidence that VEGF may not only have a role in regulating pituitary adenoma neovascularization but also, through VEGFR-1, may affect pituitary adenoma pathophysiology by modulating growth, cell cycle progression and survival of the adenoma cells.